Xenetic Biosciences
XBIO
8 hedge funds and large institutions have $758K invested in Xenetic Biosciences in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and closing their positions.
15% more capital invested
Capital invested by funds: $657K → $758K (+$100K)
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.25K |
| 2 |
RE
RBC Europe
London,
United Kingdom
|
-$2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$251 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $696K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $25K | +$24.3K | +97 | New |
|
|
PAM
3
Panagora Asset Management
Boston,
Massachusetts
| $18K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $6K | -$2.25K | -9 | -29% |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $5K | -$251 | -1 | -5% |
|
6
Morgan Stanley
New York
| $4K | – | – | – |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $2.73K | -$2K | -8 | -42% |
|
|
OIA
8
OneDigital Investment Advisors
Overland Park,
Kansas
| $1K | – | – | – |
|
XBIO Hedge Fund Activity: Q1 2018 in Review
8 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2018, worth a combined $758K — up 15% from $657K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XBIO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $24.3K. The largest seller was UBS Group, cutting an estimated $2.25K.
- 8 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2018, up from 7 in Q4 2017.
- Funds reported $758K of Xenetic Biosciences stock for Q1 2018, up 15% quarter-over-quarter.
- 1 fund opened new Xenetic Biosciences positions in Q1 2018 and 0 closed out, a net change of +1 holder.
- The largest Xenetic Biosciences buyer in Q1 2018 was Citadel Advisors, an estimated $24.3K added.
- The largest Xenetic Biosciences seller in Q1 2018 was UBS Group, an estimated $2.25K sold.
Based on aggregated 13F filings for Q1 2018.